• Ikuya Miki, Tsutomu Nakamura, Akiko Kuwahara, Motohiro Yamamori, Kohshi Nishiguchi, Takao Tamura, Tatsuya Okuno, Hideaki Omatsu, Shigeto Mizuno, Midori Hirai, Takeshi Azuma, and Toshiyuki Sakaeda.
• Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
• Int J Med Sci. 2012 Jan 1; 9 (9): 748756748-56.

ObjectiveChemotherapy-related toxicities are difficult to predict before treatment. In this study, we investigated whether thyroid hormone receptor beta (THRB) genetic polymorphisms can serve as a potential biomarker in patients with esophageal squamous cell carcinoma (ESCC).MethodsForty-nine Japanese patients with ESCC who received a definitive chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin in conjunction with concurrent irradiation were retrospectively analyzed. Severe acute toxicities, including leukopenia, stomatitis, and cheilitis, were evaluated according to 6 single nucleotide polymorphisms (SNPs) in the gene; the intronic SNPs of rs7635707 G/T, rs6787255 A/C, rs9812034 G/T, and rs9310738 C/T and the SNPs in the 3'-untranslated region (3'-UTR) of rs844107 C/T and rs1349265 G/A.ResultsDistribution of the 4 intronic SNPs, but not the 2 SNPs in the 3'-UTR, showed a significant difference between patients with and without severe acute leukopenia. Stomatitis and cheilitis were not associated with any of the 6 analyzed SNPs. Frequency of haplotype of the 4 intronic SNPs reached approximately 97% with the 2 major haplotypes G-A-G-C (73.4%) and T-C-T-T (23.5%).ConclusionsTHRB intronic SNPs can provide useful information on CRT-related severe myelotoxicity in patients with ESCC. Future studies will be needed to confirm these findings.

43 keywords...

hide…